Gerardo Ferbeyre, a research member at the Institute, and Sebastian Igelmann, a doctoral student in his laboratory and first author of the study, have made a discovery that opens a new avenue for potential cancer therapies. The two scientists published a study in Molecular Cell showing that an enzyme complex called HTC (hydride transfer complex) can inhibit cell aging.
When cells age, a state called “cellular senescence” occurs and cells stop dividing. HTC, composed of three enzymes, may be a potential target for stopping the growth of cancer cells in certain types of cancer, including prostate cancer.
THE INSTITUTE’S SCIENTIFIC DAY: 30 years of innovation, excellence, success and succession!
12 January 2021
For 30 years now, hundreds of students have passed through the Institute and left their mark there, an essential contribution […]
Dr. Simon Turcotte’s team won two grants totaling more than $ 2M for a first clinical study in cell therapy
16 December 2020
Dr’s team Simon Turcotte, researcher at the Institute, obtained a first grant from $ 675,000 from the granting body BioCanRx […]